The Preclinical Stage Partnering Terms and Agreements in Pharma and
Biotech report provides comprehensive understanding and unprecedented
access to the preclinical stage partnering deals and agreements entered
into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how
and why companies enter preclinical stage partnering deals. The majority
of deals are where the licensee obtains a right or an option right to
license the licensors product or compound. These deals tend to be
multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
do not.
This report contains over 2,200 links to online copies of actual
preclinical stage deals and contract documents as submitted to the
Securities Exchange Commission by companies and their partners. Contract
documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of
which will have a significant impact on each party’s ability to derive
value from the deal.
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of why companies
partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies.
Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of preclinical stage
deal making since 2007. Deals are listed by headline value, signed by
bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC
a link provides online access to the contract.
Chapter 6 provides a detailed analysis of
preclinical stage payment terms including average headline, upfront,
milestone and royalty rates for preclinical deals.
Chapter 7 provides a review of the leading preclinical stage deal by headline value.
Chapter 8 provides a comprehensive listing of the
top 50 big pharma and big biotech companies with a brief summary
followed by a comprehensive listing of preclinical stage deals, as well
as contract documents available in the public domain. Where available,
each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on
demand.
To Read The Complete Report with : http://www.marketresearchreports.biz/analysis-details/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech
Chapter 9 provides a comprehensive and detailed
review of preclinical stage partnering deals signed and announced since
2007, where a contract document is available in the public domain. The
chapter is organized by company A-Z, stage of development at signing,
deal type (collaborative R&D, co-promotion, licensing etc), and
specific therapy focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2007 organized by stage of development.
The report also includes numerous tables and figures that
illustrate the trends and activities in preclinical stage partnering and
deal making since 2007.
In addition, a comprehensive appendix is provided organized by
partnering company A-Z, deal type, therapy focus and technology type.
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development
and commercialization of preclinical stage products and compounds.
Latest
Report:
Antibiotics
Partnering Terms and Agreements: http://www.marketresearchreports.biz/analysis/167594
The Antibiotics Partnering
Agreements report provides an understanding and access to the antibiotics
partnering deals and agreements entered into by the worlds leading healthcare
companies. Trends in antibiotics partnering deals Disclosed headlines,
upfronts, milestones and royalties by stage of development Antibiotics
partnering contract documents Top antibiotics deals by value The Antibiotics
Partnering Terms and Agreements report provides an understanding and access to
the antibiotics partnering deals and agreements entered into by the worlds
leading healthcare companies. The report provides a detailed
understanding and analysis of how and why compani...
No comments:
Post a Comment